Antimicrobial susceptibilities of clinical isolates of vancomycin- resistant enterococci in Taiwan

Journal of the Formosan Medical Association

Volumn 98, Issue 1, 1999, Pages 45-48

  Hsueh, Po Ren ^a   Wu, Jiunn Jong ^b   Lu, Jang Jih ^c   Teng, Lee Jene ^d   Luh, Kwen Tay ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial susceptibility; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; IMIPENEM; ORITAVANCIN; PENICILLIN G; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TAIWAN;

DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; TAIWAN; VANCOMYCIN;

EID: 0033058709     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Murray BE: The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.
2. Moellering RC Jr: Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196-9.
3. Facklam RR, Sahm DF: Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, et al, eds. Manual of Clinical Microbiology, 6th ed. Washington, DC: American Society for Microbiology, 1995:308-14.
4. Centers for Disease Control and Prevention: Nosocomial enterococcal resistance to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993; 42:597-9.
5. Spera RV Jr, Farber BF: Multidrug-resistant Enterococcus faecium. Drugs 1994;48:678-88.
6. Freeman C, Robinson A, Cooper B, et al: In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 1995;21:47-50.
7. Evans PA, Norden CW, Rhoads S: In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci [Letter]. Antimicrob Agents Chemother 1997;41:1406.
8. Bonilla HF, Perri MB, Kauffman CA: Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Microbiol Infect Dis 1996;25:127-31.
9. Ristow TA, Noskin GA, Warren JR: In vitro activity of RP59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Microb Drug Resist 1995;1:335-9.
10. Collins LA, Malanoski GJ, Eliopoulos GM: In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:598-601.
11. Jones RN, Barrett MS, Erwin ME: In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1996;41:488-93.
12. Ben RJ, Lu JJ, Young TG, et al: Clinical isolation of vancomycin-resistant Enterococcus faecalis in Taiwan. J Formos Med Assoc 1996;95:946-9.
13. Perng CL, Lu JJ, Chi WM: Characterization of vancomycin-resistant enterococci isolated in northern Taiwan. In: Proceedings of the Annual Meeting of the Chinese Society of Microbiology, 1997, Taipei, Taiwan. Taipei: Chinese Society of Microbiology, 1997. [Abstract]
14. Sheu SM, Huang AH, Wu JJ: Characterization of vancomycin-resistant enterococci in southern Taiwan. In: Proceedings of the Annual Meeting of the Chinese Society of Microbiology 1997, Taipei, Taiwan. Taipei: Chinese Society of Microbiology, 1997. [Abstract]
15. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility Testing: Eighth Informational Supplement, NCCLS Document M100-S8. Villanova, PA: National Committee for Clinical Laboratory Standards, 1998.
16. Livornese LL, Dias S, Samel C, et al: Hospital-acquired infection with vancomycin-resistant Enterococcus faecium by electronic thermometer. Ann Intern Med 1992;117: 112-6.
17. Feldman RJ, Paul SM, Silber JL: An analysis of treatment of patients with vancomycin-resistant enterococcal bacteremia. Infect Dis Clin Prac 1996;5: 440-5.